ArticleEndocrine2007
Expression and localization of cystic fibrosis transmembrane conductance regulator in the rat endocrine pancreas.
Article in Endocrine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 76 citations in OpenAlex.
- Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study.Pediatric diabetes · 2013Trial
- The endocrine complications of cystic fibrosis.Nature reviews. Endocrinology · 2026Review
- Glycemia and Insulin Secretion in Cystic Fibrosis 2 Years After Elexacaftor/Tezacaftor/Ivacaftor: PROMISE-ENDO.The Journal of clinical endocrinology and metabolism · 2025Observational
- Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status.Signal transduction and targeted therapy · 2025Review
- Pancreas and islet morphology in cystic fibrosis: clues to the etiology of cystic fibrosis-related diabetes.Frontiers in endocrinology · 2023Review
- The role of modulators in cystic fibrosis related diabetes.Journal of clinical & translational endocrinology · 2022Article
- Cystic Fibrosis-Related Diabetes (CFRD): Overview of Associated Genetic Factors.Diagnostics (Basel, Switzerland) · 2021Review
- Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2021Article
- Understanding the Pancreatic Islet Microenvironment in Cystic Fibrosis and the Extrinsic Pathways Leading to Cystic Fibrosis Related Diabetes.Clinical medicine insights. Endocrinology and diabetes · 2021Review
- Mechanisms of Post-Pancreatitis Diabetes Mellitus and Cystic Fibrosis-Related Diabetes: A Review of Preclinical Studies.Frontiers in endocrinology · 2021Review
- Islet Function in the Pathogenesis of Cystic Fibrosis-Related Diabetes Mellitus.Clinical medicine insights. Endocrinology and diabetes · 2021Review
- Cystic fibrosis-related diabetes: The unmet need.World journal of diabetes · 2020Article
- Increased expression of anion transporter SLC26A9 delays diabetes onset in cystic fibrosis.The Journal of clinical investigation · 2020Article
- Heterogeneous expression of CFTR in insulin-secreting β-cells of the normal human islet.PloS one · 2020Article
- Chloride transporters and channels in β-cell physiology: revisiting a 40-year-old model.Biochemical Society transactions · 2019Review
- Islet Hormone and Incretin Secretion in Cystic Fibrosis after Four Months of Ivacaftor Therapy.American journal of respiratory and critical care medicine · 2019Article
- Cystic Fibrosis-Related Diabetes: Pathophysiology and Therapeutic Challenges.Clinical medicine insights. Endocrinology and diabetes · 2019Review
- Understanding childhood diabetes mellitus: new pathophysiological aspects.Journal of inherited metabolic disease · 2018Review
- Cystic Fibrosis-Related Diabetes.Frontiers in endocrinology · 2018Review
- CFTR Influences Beta Cell Function and Insulin Secretion Through Non-Cell Autonomous Exocrine-Derived Factors.Endocrinology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Impaired glucose tolerance and overt diabetes mellitus are becoming increasingly common complications of cystic fibrosis (CF), most probably merely as a result of increased life expectancy. In order to understand the pathophysiology of cystic fibrosis-related diabetes (CFRD), knowledge on the possible expression and cell distribution of the cystic fibrosis transmembrane conductance regulator (CFTR) protein within the endocrine pancreas is required. In this report, we establish the first evidence for expression of CFTR protein in rat pancreatic islets by using independent techniques. First reverse transcriptase-polymerase chain reaction (RT-PCR) amplification showed that CFTR mRNA is present in isolated islets of Langerhans. Furthermore, the analysis of flow cytometry-separated islet cells indicated that the level of CFTR transcripts is significantly higher in the non-beta than in beta-cell populations. The expression of CFTR protein in rat islet cells was also demonstrated by Western blotting and the level of expression was also found significantly higher in the non-beta than in beta-cell populations. Last, in situ immunocytochemistry studies with two monoclonal antibodies recognizing different CFTR epitopes indicated that CFTR expression occurs mainly in glucagon-secreting alpha-cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.